Trial Profile

A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Daratumumab (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Tiragolumab (Primary)
Indications B-cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Genentech

06 Apr 2023 Status changed from active, no longer recruiting to discontinued due to slow recruitment.
19 Jan 2023 Planned End Date changed from 1 Dec 2023 to 28 Mar 2023.
19 Jan 2023 Planned primary completion date changed from 1 Sep 2023 to 28 Mar 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com